OTCQB:PKTX is likely a company you've never heard of. It has an anti-aging molecule called AAGP. Very simply put, AAGP enhances cell life and survivability. The molecule can be used for nearly anything imaginable. Cancer treatment, organ transplants, diabetes treatment, retinal regeneration, the list goes on and on. One area that I think makes them a particular interesting biotech candidate is the molecule's potential use in immunotherapy. The molecule is currently being tested for various applications and is also in human trials for diabetes treatment. It currently trades at just over .17 and has a paltry $43 million market cap. The company's CEO has been buying at an unprecedented rate. This may seem like and unlikely candidate but for comparison sake, MRK recently purchased Peloton Therapeutics for over $1 billion with incentives that could bring the price to over $2 billion. Peloton is a clinical stage and yet still commanded a $2 billion price tag.